A Dose-Ranging Study of IPH2201 in Patients With Gynecologic Malignancies
The purpose of this study is to test the safety of a new drug, IPH2201, to see what effects
it has on this type of cancer.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society